R4 Releases Wal-Mart Schedule II Compliance Package - InformationWeek

InformationWeek is part of the Informa Tech Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them.Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

IoT
IoT
Software // Information Management
News
4/26/2004
10:45 AM
50%
50%

R4 Releases Wal-Mart Schedule II Compliance Package

R4 Global Services announces a packaged set of hardware and software components designed for pharmaceutical firms charged with meeting Wal-Mart's Schedule II RFID mandate.

R4 Global Services last week announced a packaged set of hardware and software components designed for pharmaceutical firms trying to meet Wal-Mart's Schedule II RFID mandate.

Schedule II compliance as laid out by Wal-Mart requires drug companies to apply RFID tags at the item level on U.S. DEA Schedule II pharmaceutical products they ship to the retail giant. The mandate also requires that manufacturers collect RFID tag information and make it synchronizable with UCCnet, an item-registration standard established by the Uniform Code Council.

Schedule II drugs are highly regulated, prescription narcotics such as Ritalin and Morphine.

R4's Accelerate Solution for Schedule II Compliance is designed to address drug companies' short-term need for compliance and their long-term need to develop a more scalable technology architecture using RFID in the supply chain.

The package includes third-party tag readers, a print-and-apply application for production lines, a PC controller responsible for data storage, middleware that interfaces with readers and antennas, and basic ERP integration.

RFID technology is cost-effective for use with Schedule II drugs because of their relative expense, which ranges up to $40,000 at the pallet level, said R4 vice president of technology Charles Rice.

San Francisco-based R4 is charging between $125,000 and $175,000 for the package, depending on the number of drug products involved and the volume being shipped.

We welcome your comments on this topic on our social media channels, or [contact us directly] with questions about the site.
Comment  | 
Print  | 
More Insights
InformationWeek Is Getting an Upgrade!

Find out more about our plans to improve the look, functionality, and performance of the InformationWeek site in the coming months.

Slideshows
10 Things Your Artificial Intelligence Initiative Needs to Succeed
Lisa Morgan, Freelance Writer,  4/20/2021
News
Tech Spending Climbs as Digital Business Initiatives Grow
Jessica Davis, Senior Editor, Enterprise Apps,  4/22/2021
Commentary
Optimizing the CIO and CFO Relationship
Mary E. Shacklett, Technology commentator and President of Transworld Data,  4/13/2021
White Papers
Register for InformationWeek Newsletters
Video
Current Issue
Planning Your Digital Transformation Roadmap
Download this report to learn about the latest technologies and best practices or ensuring a successful transition from outdated business transformation tactics.
Slideshows
Flash Poll